膀胱癌（BC）是一种常见且严重的癌症，位居全球十大最常见恶性肿瘤之列。由于BC的发病率高、癌细胞具有侵袭性以及对药物的抗性，治疗这种疾病在临床护理中变得越来越具有挑战性。长链非编码RNA（lncRNA）是一类不编码蛋白质且长度超过200个核苷酸的RNA转录本。它们在控制细胞途径和不同类型癌症的发生、发展和进展过程中发挥重要作用。最近高通量基因测序技术的进展已经揭示了BC中多种差异表达的lncRNA，这些lncRNA表明异常的表达。在本综述中，我们总结了这些lncRNA已被发现对BC的发展中所涉及的多种功能产生影响，包括增殖、细胞生长、迁移、转移、凋亡、上皮间充质转化以及化疗和放疗抵抗。此外，lncRNA可能对BC患者的预后预测有所改善，表明它们作为BC患者的预后和诊断生物标志物的未来应用。这篇综述突出了基于积极的研究结果，产生了CRISPR/Cas系统、siRNA、shRNA、反义寡核苷酸和载体等基因工具和抗肿瘤药物，使得使用lncRNA变得越来越受关注。版权所有 © 2023 The Authors. 由Elsevier Masson SAS出版。保留所有权利。

Bladder cancer (BC) is a common and serious type of cancer that ranks among the top ten most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the aggressive nature of cancer cells, and their resistance to medication, managing this disease has become a growing challenge in clinical care. Long noncoding RNAs (lncRNAs) are a group of RNA transcripts that do not code for proteins and are more than 200 nucleotides in length. They play a significant role in controlling cellular pathways and molecular interactions during the onset, development and progression of different types of cancers. Recent advancements in high-throughput gene sequencing technology have led to the identification of various differentially expressed lncRNAs in BC, which indicate abnormal expression. In this review, we summarize that these lncRNAs have been found to impact several functions related to the development of BC, including proliferation, cell growth, migration, metastasis, apoptosis, epithelial-mesenchymal transition, and chemo- and radio-resistance. Additionally, lncRNAs may improve prognosis prediction for BC patients, indicating a future use for them as prognostic and diagnostic biomarkers for BC patients. This review highlights that genetic tools and anti-tumor agents, such as CRISPR/Cas systems, siRNA, shRNA, antisense oligonucleotides, and vectors, have been created for use in preclinical cancer models. This has led to a growing interest in using lncRNAs based on positive research findings.Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.